|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Rafael Padilla||CEO & Exec. Director||621,53k||N/D||1978|
|Ms. Karin de Jong||CFO & Exec. Director||410,14k||N/D||1979|
|Ms. Vera Bakker||Chief Operating Officer||N/D||N/D||1972|
|Karen Berg||Global Investor Relations Mang.||N/D||N/D||N/D|
|Mr. Johan Verlinden||Head of Legal, Mergers & Acquisitions||N/D||N/D||N/D|
|Mr. Ivan Jose Marostica||Area Leader Latin America||N/D||N/D||N/D|
|Mr. Andrew C. Pulido||Area Leader North America||N/D||N/D||N/D|
Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
L'ISS Governance QualityScore di Fagron NV al 1 settembre 2022 è 4. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 3; diritti degli azionisti: 6; retribuzione: 5.